270 related articles for article (PubMed ID: 7595233)
1. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein.
Hara I; Takechi Y; Houghton AN
J Exp Med; 1995 Nov; 182(5):1609-14. PubMed ID: 7595233
[TBL] [Abstract][Full Text] [Related]
2. Tumor immunity and autoimmunity induced by immunization with homologous DNA.
Weber LW; Bowne WB; Wolchok JD; Srinivasan R; Qin J; Moroi Y; Clynes R; Song P; Lewis JJ; Houghton AN
J Clin Invest; 1998 Sep; 102(6):1258-64. PubMed ID: 9739060
[TBL] [Abstract][Full Text] [Related]
3. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity.
Naftzger C; Takechi Y; Kohda H; Hara I; Vijayasaradhi S; Houghton AN
Proc Natl Acad Sci U S A; 1996 Dec; 93(25):14809-14. PubMed ID: 8962137
[TBL] [Abstract][Full Text] [Related]
4. Coupling and uncoupling of tumor immunity and autoimmunity.
Bowne WB; Srinivasan R; Wolchok JD; Hawkins WG; Blachere NE; Dyall R; Lewis JJ; Houghton AN
J Exp Med; 1999 Dec; 190(11):1717-22. PubMed ID: 10587362
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.
Overwijk WW; Lee DS; Surman DR; Irvine KR; Touloukian CE; Chan CC; Carroll MW; Moss B; Rosenberg SA; Restifo NP
Proc Natl Acad Sci U S A; 1999 Mar; 96(6):2982-7. PubMed ID: 10077623
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma.
Hirschowitz EA; Leonard S; Song W; Ferris B; Leopold PL; Lewis JJ; Bowne WB; Wang S; Houghton AN; Crystal RG
Gene Ther; 1998 Jul; 5(7):975-83. PubMed ID: 9813669
[TBL] [Abstract][Full Text] [Related]
7. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
van Elsas A; Hurwitz AA; Allison JP
J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
[TBL] [Abstract][Full Text] [Related]
8. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.
Saenger YM; Li Y; Chiou KC; Chan B; Rizzuto G; Terzulli SL; Merghoub T; Houghton AN; Wolchok JD
Cancer Res; 2008 Dec; 68(23):9884-91. PubMed ID: 19047169
[TBL] [Abstract][Full Text] [Related]
9. A melanosomal membrane protein is a cell surface target for melanoma therapy.
Takechi Y; Hara I; Naftzger C; Xu Y; Houghton AN
Clin Cancer Res; 1996 Nov; 2(11):1837-42. PubMed ID: 9816138
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic tumor immunity induced by polyimmunization with melanoma antigens gp100 and TRP-2.
Mendiratta SK; Thai G; Eslahi NK; Thull NM; Matar M; Bronte V; Pericle F
Cancer Res; 2001 Feb; 61(3):859-63. PubMed ID: 11221870
[TBL] [Abstract][Full Text] [Related]
11. Multiple pathways to tumor immunity and concomitant autoimmunity.
Turk MJ; Wolchok JD; Guevara-Patino JA; Goldberg SM; Houghton AN
Immunol Rev; 2002 Oct; 188():122-35. PubMed ID: 12445286
[TBL] [Abstract][Full Text] [Related]
12. Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy.
Engelhard VH; Bullock TN; Colella TA; Sheasley SL; Mullins DW
Immunol Rev; 2002 Oct; 188():136-46. PubMed ID: 12445287
[TBL] [Abstract][Full Text] [Related]
13. GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1.
Rausch MP; Irvine KR; Antony PA; Restifo NP; Cresswell P; Hastings KT
J Immunol; 2010 Sep; 185(5):2828-35. PubMed ID: 20668223
[TBL] [Abstract][Full Text] [Related]
14. Autoimmune etiology of generalized vitiligo.
Le Poole IC; Luiten RM
Curr Dir Autoimmun; 2008; 10():227-43. PubMed ID: 18460889
[TBL] [Abstract][Full Text] [Related]
15. Fc receptors are required in passive and active immunity to melanoma.
Clynes R; Takechi Y; Moroi Y; Houghton A; Ravetch JV
Proc Natl Acad Sci U S A; 1998 Jan; 95(2):652-6. PubMed ID: 9435247
[TBL] [Abstract][Full Text] [Related]
16. Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo.
Bronte V; Apolloni E; Ronca R; Zamboni P; Overwijk WW; Surman DR; Restifo NP; Zanovello P
Cancer Res; 2000 Jan; 60(2):253-8. PubMed ID: 10667570
[TBL] [Abstract][Full Text] [Related]
17. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.
Yee C; Thompson JA; Roche P; Byrd DR; Lee PP; Piepkorn M; Kenyon K; Davis MM; Riddell SR; Greenberg PD
J Exp Med; 2000 Dec; 192(11):1637-44. PubMed ID: 11104805
[TBL] [Abstract][Full Text] [Related]
18. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection.
Schreurs MW; de Boer AJ; Figdor CG; Adema GJ
Cancer Res; 1998 Jun; 58(12):2509-14. PubMed ID: 9635569
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor activity of human IgG1 anti-gp75 TA99 mAb against B16F10 melanoma in human FcgammaRI transgenic mice.
Boross P; Jansen JH; van Tetering G; Nederend M; Brandsma A; Meyer S; Torfs E; van den Ham HJ; Meulenbroek L; de Haij S; Leusen JH
Immunol Lett; 2014 Aug; 160(2):151-7. PubMed ID: 24613852
[TBL] [Abstract][Full Text] [Related]
20. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.
Sanchez-Perez L; Kottke T; Diaz RM; Ahmed A; Thompson J; Chong H; Melcher A; Holmen S; Daniels G; Vile RG
Cancer Res; 2005 Mar; 65(5):2009-17. PubMed ID: 15753401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]